REG - IXICO plc - Result of GM, Issue of Equity & TVR

IXICOAnnouncement

25/10/2024 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241025:nRSY7236Ja&default-theme=true

RNS Number : 7236J  IXICO plc  25 October 2024

25 October 2024

 

 

IXICO PLC

 

("IXICO" or the "Company")

 

Result of General Meeting, Issue of Equity and Total Voting Rights

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that all resolutions put to
Shareholders at the General Meeting held earlier today in connection with the
placing, subscription and retail offer announced by the Company on 8 October
2024 were duly passed, including the amendment resolutions referred to in the
announcement dated 22 October 2024.

 

 

 Resolution                                                                            For                      Against                 Withheld         Total votes cast
                                                                                       Number of votes  %       Number of votes  %      Number of votes
 1       Ordinary resolution to authorise the directors to allot shares                26,857,594       99.97%  8,194            0.03%  37,912           26,865,788
 2       Ordinary resolution to approve the Company's EMI Share Option Plan            26,676,840       99.30%  188,448          0.70%  38,412           26,865,288
 3       Special resolution to authorise the directors to disapply pre-emption rights  26,827,687       99.86%  38,101           0.14%  37,912           26,865,788

(1)     Any proxy appointments, which gave discretion to the Chairman have
been included in the "For" votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a
percentage of votes validly cast for that resolution.

(3)     A vote "Withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against", nor in the
aggregate figure of total votes cast.

 

Issue of Equity and Total Voting Rights

 

Following shareholder approval at the general meeting and conditional on
admission, 41,315,792 new ordinary shares have been allotted pursuant to the
Placing, 516,244 new ordinary shares pursuant to the Retail Offer and 789,472
pursuant to the Subscription.

 

The Company has therefore allotted a total of 42,621,508 new ordinary shares
in connection with the Fundraising.

 

Admission is expected to take place at 8.00 a.m. on or around 28 October 2024.

 

Following Admission, the total number of Ordinary Shares in the capital of the
Company in issue will be 92,668,598 with each Ordinary Share carrying the
right to one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the Company will be
92,668,598.

 

The above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in
the announcement of the Placing and Subscription dated 8 October 2024, unless
otherwise defined in this announcement.

 

 

For further information please contact:

 

 IXICO plc                                           +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited                   +44 (0) 20 7220 0500

 (Nominated adviser and sole broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)
 Harriet Ward (Corporate Broking)
 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on X (formerly Twitter) @IXICOnews

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFELIFLEFIS